---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 33 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### FDA-approved prescribing information for AD109

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

#### Phase 3 trials: most common adverse events and serious adverse events (company statement)

> “Across both Phase 3 studies, no SAEs or deaths were reported as related to AD109. Most AEs were reported as mild in severity, and the common AEs were consistent with previous trials of AD109. The tolerability profile was consistent with the individual components of the combination. In our Phase 3 clinical trials, dry mouth, insomnia, and nausea were the most common treatment-related AEs (Figure 29; Figure 30).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-3"></a>

#### Pooled phase 3 analysis: treatment-emergent adverse events

> “TEAEs were predominantly mild, with ≥1 TEAE reported by 500 (76.6%) participants on AD109 and 370 (57.3%) on PBO. The most common TEAEs were dry mouth, insomnia, nausea, urinary hesitation, somnolence, and constipation. No AD109-related serious TEAEs were identified.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-2.1.2.7.1-4"></a>

#### SynAIRgy: treatment-emergent adverse events in the safety analysis set

| Measure | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
| --- | --- | --- |
| Any TEAE | “230 (70.8)” | “149 (46.7)” |
| Any treatment-related TEAE | “190 (58.5)” | “75 (23.5)” |
| Any severe TEAE | “15 (4.6)” | “10 (3.1)” |
| Any TEAE leading to treatment discontinuation | “69 (21.2)” | “10 (3.1)” |
| Dry mouth | “115 (35.4)” | “29 (9.1)” |
| Insomnia (initial insomnia, insomnia, and middle insomnia) | “67 (20.6)” | “15 (4.7)” |
| Nausea | “37 (11.4)” | “2 (0.6)” |
| Urinary hesitation | “29 (8.9)” | “1 (0.3)” |
| Constipation | “17 (5.2)” | “4 (1.3)” |
| Somnolence | “17 (5.2)” | “10 (3.1)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.7.1-5"></a>

#### LunAIRo: adverse events

> “Adverse events (AEs) were predominantly mild, with ≥1 AE reported by 272 (82.9%) participants with AD109 and 223 (68.2%) with PBO. The most common AEs with AD109 (≥5% of participants and >PBO) were dry mouth, insomnia, nausea, urinary hesitation, somnolence, headache, dyspepsia, urinary tract infection, constipation, and dizziness. No treatment-related serious AEs were identified.”

Source: [Patel et al. (2025b)](https://journal.chestnet.org/article/S0012-3692%2825%2905443-1/fulltext)

<a id="topic-2.1.2.7.1-6"></a>

#### Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26

> “TEAEs leading to treatment discontinuation by Week 26 was 25.0% (163/653) in participants receiving AD109 and 6.7% (43/646) receiving PBO.”

Source: [Patel et al. (2026a)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.015/8712277)

<a id="topic-2.1.2.7.1-7"></a>

#### Pooled phase 3 analysis: overall treatment discontinuation by week 26

> “Treatment was discontinued by Week 26 in 227 (35.2%) participants randomized to AD109 and 100 (15.5%) to PBO.”

Source: [Patel et al. (2026b)](https://academic.oup.com/ajrccm/article/212/Supplement_2/aamag286.317/8712356)

<a id="topic-2.1.2.7.1-8"></a>

#### Treatment discontinuation due to adverse events and overall treatment discontinuation, SynAIRgy and LunAIRo

> “In SynAIRgy, among participants randomized in the main cohort, AEs led to treatment discontinuation prior to month 6 in 21.2% of participants receiving AD109 compared with 3.1% on placebo, contributing to overall discontinuation rates of 34.6% for AD109 and 16.5% for placebo at month 6. In LunAIRo, among participants randomized in the main cohort, AE–related discontinuation occurred in 23.7% of participants receiving AD109 and 6.6% receiving placebo by month 6, and remained the most common reason for discontinuation by month 12 (28.6% vs 10.0%), contributing to overall discontinuation rates of 46.5% for AD109 and 25.1% for placebo at month 12.”
> “Importantly, for both trials, AE-related discontinuations occurred predominantly early after treatment initiation, with markedly fewer events later in the treatment period (Figure 32).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-9"></a>

#### SynAIRgy: adverse events leading to treatment discontinuation

> “The primary (occurring in  ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

| Treatment-emergent adverse event leading to treatment discontinuation | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
| --- | --- | --- |
| Insomnia | “16 (4.9)” | “0” |
| Urinary hesitation | “8 (2.5)” | “0” |
| Nausea | “7 (2.2)” | “0” |
| Erectile dysfunction/sexual dysfunction | “5 (1.5)” | “0” |
| Dry mouth | “4 (1.2)” | “0” |
| Hypertension | “3 (0.9)” | “0” |
| Palpitations | “3 (0.9)” | “0” |
| Urinary retention | “2 (0.6)” | “0” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-2.1.2.7.1-10"></a>

#### Insomnia: discontinuation, onset, duration, and severity in the phase 3 trials

> “Insomnia was the main reason for discontinuation in 4.9% of participants in SynAIRgy and 3% of participants in LunAIRo. Insomnia was not assessed at baseline in a standardized manner in the Phase 3 program for SynAIRgy.”
> “The median time of first onset for insomnia was a median (IQR) of 3 days (1 to 12) and the duration of the first event was 16 (6 to 67) days. Insomnia was mild for 79.2% of cases, moderate for 17.4% and severe for 3.4%.”
> “Oxnimbi has been shown to cause undesirable side effects, such as its ability to cause or worsen insomnia.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-11"></a>

#### Cardiovascular effects: major adverse cardiovascular events and 24-hour ambulatory blood pressure in the phase 3 trials

> “Across the pooled tolerability dataset, no (n=0) MACE were reported in participants receiving AD109. Five (n=5) MACE were reported in participants receiving placebo. The LunAIRo study included an assessment of 24-hour monitoring of ambulatory blood pressure at week 4, demonstrating small changes in mean arterial pressure (1.9 mmHg) and heart rate (4.6 bpm).”
> “Overall, changes in blood pressure and heart rate were small although a small subgroup of participants showed tachycardia while on AD109.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-12"></a>

#### Cardiovascular effects: heart rate and blood pressure, pooled phase 3 safety analysis set

| Measure | AD109 (n = 653) | Placebo (n = 646) | P value |
| --- | --- | --- | --- |
| Heart rate (beats/min), mean change from baseline to week 26, evening before PSG, mean (SD) | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate (beats/min), mean change from baseline to week 26, morning after PSG, mean (SD) | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Systolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.9 (12.0)” | “-1.2 (12.3)” | Not reported |
| Diastolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.7 (8.4)” | “-1.5 (7.8)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-13"></a>

#### Cardiovascular effects: overnight heart rate over 4 weeks (MARIPOSA)

> “Placebo-adjusted mean (95% confidence interval) change from baseline in overnight heart rate was slightly higher in all treatment groups: 7.7 (5.7–9.6), 5.1 (2.9–7.4), and 5.5 (3.3–7.1) beats/min for Ato75, Ad109 2.5/75 mg, and AD109 5/75 mg, respectively (Table 7).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-2.1.2.7.1-14"></a>

#### Cardiovascular effects: populations excluded from the phase 3 trials and suggested caution

> “However, while these changes were small on average, their clinical relevance may vary depending on individual patient characteristics, and careful consideration may be warranted in patients with uncontrolled or resistant hypertension, heart failure, or tachyarrhythmias. Notably, such patients were excluded from the clinical trials.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.7.1-15"></a>

#### Adverse events of special interest in the phase 3 trials

> “Adverse events of special interest include urinary issues, cardiovascular symptoms, suicidal ideation, daytime sleepiness, motor vehicle accidents, and anticholinergic effects, with a focus on recording patient-reported experiences.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-2.1.2.7.1-16"></a>

#### Attribution of adverse events to the noradrenergic and antimuscarinic components

> “The adverse event profile is consistent with the mechanism of action of AD109. Noradrenergic stimulation may contribute to wake-promoting effects, including insomnia and nausea, while antimuscarinic activity may explain anticholinergic symptoms such as urinary hesitancy and dry mouth.”

Source: [Horner et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316936/)

<a id="topic-2.1.2.7.1-17"></a>

#### Phase 1 tolerability (APC-001 and APC-002)

> “In Study APC-001 and APC-002 there were no SAEs, study drug-related treatment emergent (TE) AEs leading to study drug discontinuation or interruption.”
> “In Study APC-002 the most common TEAE was nausea, which was experienced by six subjects (26.1%) treated with AD109. Other common TEAEs included vomiting, dizziness, dry mouth, flushing, asthenia, and COVID-19.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.1.2.7.1-18"></a>

#### Meta-analysis of atomoxetine combination trials: adverse events, dry mouth, and difficulty with urination

> “While the ato group resulted in a significant increase in total AEs (RR = 1.65, 95% CI = 1.28, 2.13, P = 0.0001, I2 = 7%), dry mouth (29.2% vs 9.5%, P = 0.002) and difficulty with urination (10.7% vs 0.8%, P = 0.05).”

Source: [Zhao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42269187/)

<a id="topic-2.1.2.7.1-19"></a>

#### Atomoxetine label: boxed warning for suicidal thoughts and behaviors in children and adolescents 6 years of age and older

> “All STRATTERA-treated pediatric patients 6 years of age or older should be monitored and observed closely for suicidal thoughts and behavior, clinical worsening, or unusual changes in behavior, especially during the initial months of therapy or at times of dosage changes.”
> “STRATTERA increased the risk of suicidal ideation in pediatric patients aged 6 years of age and older with attention-deficit/hyperactivity disorder (ADHD) in short-term studies.”
> “A similar analysis in adult patients treated with STRATTERA for ADHD did not reveal an increased risk of suicidal ideation or behavior.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-20"></a>

#### Atomoxetine label: contraindications

> “Taking, or within 14 days of stopping, a monoamine oxidase inhibitor (MAOI)”
> “With narrow angle glaucoma. In clinical trials, STRATTERA use was associated with an increased risk of mydriasis.”
> “With pheochromocytoma or a history of pheochromocytoma.”
> “With severe cardiac or vascular disorders whose condition would be expected to deteriorate if they had a clinically important increase in blood pressure or heart rate (e.g., 15 to 20 mm Hg in blood pressure or 20 beats per minute in heart rate)”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-21"></a>

#### Atomoxetine label: severe liver injury

> “STRATTERA should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury.”
> “Postmarketing reports indicate that STRATTERA can cause severe liver injury.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-22"></a>

#### Atomoxetine label: serious cardiovascular reactions

> “Consideration should be given to not treating adults with STRATTERA with clinically significant cardiac abnormalities.”
> “Adults: Sudden deaths, stroke, and myocardial infarction have been reported in STRATTERA-treated adults at the recommended ADHD dosage.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-23"></a>

#### Atomoxetine label: increases in blood pressure and heart rate

> “STRATTERA should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease.”
> “Heart rate and blood pressure should be measured at baseline, following STRATTERA dosage increases, and periodically while on therapy to detect possible clinically important increases in heart rate and blood pressure.”
> “In placebo-controlled adult ADHD studies, tachycardia was identified as an adverse reaction in 1.5% (8/540) of STRATTERA-treated patients compared with 0.5% (2/402) of placebo-treated patients.”
> “Orthostatic hypotension and syncope have been reported in STRATTERA-treated patients.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-24"></a>

#### Atomoxetine label: psychotic or manic symptoms, bipolar disorder screening, and aggressive behavior

> “If psychotic or manic symptoms occur, consider discontinuing STRATTERA.”
> “Patients with bipolar disorder or risk factors for bipolar disorder may be at increased risk of developing mania or mixed episodes during treatment with STRATTERA.”
> “There is evidence that STRATTERA may cause the emergence or worsening of aggressive behavior or hostility.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-25"></a>

#### Atomoxetine label: effects on urine outflow

> “A complaint of urinary retention or urinary hesitancy should be considered potentially related to STRATTERA. In adult ADHD controlled studies, the incidence of urinary retention (1.7%, 9/540) and urinary hesitation (5.6%, 30/540) were increased among STRATTERA-treated patients compared with placebo-treated patients (0%, 0/402; 0.5%, 2/402, respectively).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-26"></a>

#### Atomoxetine label: priapism and hypersensitivity reactions

> “Prompt medical attention is required in the event of suspected priapism in STRATTERA-treated patients.”
> “Although uncommon, hypersensitivity reactions, including anaphylaxis, angioneurotic edema, urticaria, and rash, have been reported in STRATTERA-treated patients.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-27"></a>

#### Atomoxetine label: somnolence and driving

> “Patients should be instructed to use caution when driving a car or operating hazardous machinery (because of somnolence) until they are reasonably certain that their performance is not affected by STRATTERA.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-28"></a>

#### Atomoxetine label: adverse reactions and discontinuation in adult ADHD studies

> “11.3% (61/541) STRATTERA-treated patients and 3% (12/405) placebo-treated patients discontinued for adverse reactions.”
> “The most commonly observed adverse reactions in patients treated with STRATTERA (incidence of 5% or greater and at least twice the incidence in placebo patients) were: constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction, and urinary hesitation (see Table 5).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

| Adverse reaction in acute adult ADHD studies (up to 25 weeks) | STRATTERA (N=1,697) | Placebo (N=1,560) |
| --- | --- | --- |
| Nausea | “26%” | “6%” |
| Dry mouth | “20%” | “5%” |
| Insomnia | “15%” | “8%” |
| Urinary hesitation | “6%” | “1%” |

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.7.1-29"></a>

#### Oxybutynin label: contraindications

> “DITROPAN XL® is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-30"></a>

#### Oxybutynin label: angioedema

> “Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-31"></a>

#### Oxybutynin label: anticholinergic central nervous system effects

> “A variety of CNS anticholinergic effects have been reported, including hallucinations, agitation, confusion and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly in the first few months after beginning treatment or increasing the dose.”
> “If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.”
> “DITROPAN XL® should be used with caution in patients with preexisting dementia treated with cholinesterase inhibitors due to the risk of aggravation of symptoms.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-32"></a>

#### Oxybutynin label: myasthenia gravis and autonomic neuropathy

> “DITROPAN XL® should be used with caution in patients with myasthenia gravis due to the risk of aggravation of symptoms.”
> “DITROPAN XL® should be used with caution in patients with autonomic neuropathy due to the risk of aggravation of symptoms of decreased gastrointestinal motility.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-33"></a>

#### Oxybutynin label: urinary retention and gastrointestinal adverse reactions

> “DITROPAN XL® should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention”
> “DITROPAN XL®, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

<a id="topic-2.1.2.7.1-34"></a>

#### Oxybutynin label: most common adverse reactions

> “The most common (incidence ≥5%) adverse reactions were dry mouth, constipation, diarrhea, headache, somnolence, and dizziness.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
